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SUMMARY
Over the last 30 years, a number of Vibrio species found in the aquatic environment have been indicated as cause of disease in
human beings. Vibrio vulnificus is an emergent pathogen, an invasive and lethal marine bacterium related to wound infection and held
accountable for gastroenteritis and primary septicemia. It occurs quite frequently in marine organisms, mainly in mollusks. This study
aimed at isolating and identifying strains of V. vulnificus based upon the analysis of twenty samples of seabob shrimp, Xiphopenaeus
kroyeri (Heller), purchased at the Mucuripe fish market (Fortaleza, Brazil). TCBS agar was used to isolate suspect strains. Seven of
twenty-nine strains isolated from six different samples were confirmed as such by means of biochemical evidence and thus submitted
to biological assays to determine their virulence. The susceptibility of the V. vulnificus strains to a number of antibiotics was tested.
None of the V. vulnificus strains showed signs of virulence during a 24-hour observation period, possibly due to the shedding of the
capsules by the cells. As to the results of the antimicrobial susceptibility tests, the seven above-mentioned V. vulnificus strains were
found to be sensitive to nitrofurantoin (NT), ciprofloxacin (CIP), gentamicin (GN) and chloramphenicol (CO) and resistant to
clindamycin (CI), penicillin (PN) and ampicillin (AP).
KEYWORDS: Marine bacterium; Vibrio vulnificus; Shrimp; Antimicrobial susceptibility tests.
INTRODUCTION
The consumption of both mollusks and crustaceans – among the
latter, especially shrimp - has been on the increase over the past years.
According to the Brazilian Ministry of Agriculture, fishing industries in
Ceará exported 320,500 kg, 953,109 kg and 997,213 kg in 1988, 1999
and 2000, respectively. Unfortunately these foods have also been implied
in outbreaks of intoxication and intestinal infection produced by naturally
occurring marine and estuarine bacteria. Most of these bacteria are
vibrionaceans belonging to genus Vibrio. Studies describing the presence
of vibrions in seafood in temperate regions and in Asia are quite common,
and a few instances of vibrion-related disease, apart from Vibrio cholerae
01, have been reported from tropical countries. The few reports available
on the occurrence of these microorganisms in seafood, deal mostly with
Vibrio parahaemolyticus. The species Vibrio vulnificus was first
associated with disease in human beings in 1970 when a male patient
was found to have developed an infection in the leg and diarrhea after
swimming in the sea and collecting oysters22. However, the severity and
frequency of V. vulnificus infections were not appreciated until in the
late 1970s3. Epidemiological enforcement teams in four American states
along the Gulf of Mexico found an annual incidence of V. vulnificus
infections of 0.6 million cases, with a mortality rate of 22% 16 .
The present study aims at: 1) isolating and identifying V. vulnificus
strains in marine shrimp samples, 2) investigating the toxigenic potential
of the isolated bacteria through biological tests, and 3) assessing the
susceptibility of these bacteria to a number of selected antibiotics.
MATERIALS AND METHODS
The standard Vibrio vulnificus strain used in all biochemical tests
was provided by Fundação Oswaldo Cruz (FIOCRUZ) and maintained
in 3% NaCl tryptone soy agar (TSA) in a BOD incubator (model: 347
Fanem, Brazil) at 23 °C.
Twenty seabob shrimp Xiphopenaeus kroyeri (Heller) (500 g total
weight) were purchased from stalls at the Mucuripe fish market (Fortaleza,
Ceará), iced and transported in isothermic containers to the Fish
Microbiology laboratory of the Marine Sciences Institute (Instituto de
Ciências do Mar - LABOMAR, Fortaleza).
A set of 25 g samples was homogenized in 225 mL of 3% NaCl
solution and subsequently diluted (from 10-1 to 10-3) in 9 mL of the same
medium, then spread-plated on thiosulfate citrate bile saccharose (TCBS)
agar and incubated for 24 hours at 35 °C. Suspect, 2-3 mm saccharose-
negative, dull green colonies from the plates were isolated in TSA-DIFCO
and incubated once more for 24 hours at 35 °C for biochemical
confirmation8.
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The first tests involved oxidase and motility and used 1% tetramethyl-
p-phenylenodiamine and SIM (DIFCO) medium, respectively. In both
tests, positive strains were submitted to halophilism assays in 1% peptone
broth at 0, 3, 6, 8 and 10% NaCl concentrations, to ONPG and acetoine
production assays, and finally to incubation for 24 hours at 35 °C. The
morphological characteristics of the isolated strains cultured in 3% TSA
were observed by gram staining.
The pathogenicity of the V. vulnificus strains isolated from the shrimp
samples was tested in biological assays. The study employed seven groups
of three mice each and an average individual weight of 20g. Each mouse
was submitted to intraperitoneal inoculation with 0.1 mL of culture grown
in brain heart infusion (BHI) for 24 hours at room temperature. The
control consisted of a group of three mice submitted to inoculation with
0.1 mL of sterile BHI. All groups were observed for 24 hours4.
The antimicrobial susceptibility tests were performed according to
the methodology recommended by BAUER et al.1 and met the criteria
established by the NCCLS18. The following CECON antibiotics were
used in the tests: nitrofurantoin (NT), nalidixic acid (NA), tetracycline
(TT), clindamycin (CI), tobramycin (TB), ciprofloxacin (CIP), penicillin
(PN), gentamicin (GN), kanamycin (KN), cefotaxime (CTX),
erythromycin (EI), chloramphenicol (CO), amikacin (AM), ampicillin
(AP) and sulfonamide (SF). The control strains used were Escherichia
coli (ATCC 25922) and S. aureus (ATCC 25923).
RESULTS AND DISCUSSION
Seven of the 20 original samples yielded positive results. Our figures
therefore indicate a rather high incidence as compared to that (14.3%)
found for shrimp by GARCIA-MORENO & LANDGRAF9. In an
analysis of shrimp, oysters and mussels, LANDGRAF et al.15 found an
even lower incidence for shrimp (4.2%) and a relatively high incidence
for oyster (29.0%). It is a well-known fact that vibrions are found more
often in oysters due to their filtering habits and their natural presence in
the estuarine microbiota. It is therefore not uncommon for oysters to
accumulate all types of viruses and bacteria which occur in the
surrounding water.
The results reported so far regarding the isolation of Vibrio vulnificus
from shrimp have been controversial. While DePAOLA et al.7 isolated a
4.4 log MPN of bacteria in crustacean samples, DALSGAARD & HOI5
found only 3 vibrion-contaminated samples (7%) out of a batch of 46 in
a study using raw, frozen shrimp imported from Thailand and Indonesia.
However, the authors found no contamination in 61 cooked and frozen
products imported from these same countries. In view of the uncertainty
of the matter and the lack of precise knowledge about the infecting dose
of V. vulnificus, it would be desirable to establish a maximum number of
bacteria allowed in seafood, both as a reference for researchers and as a
safeguard for consumers.
 Epidemiological data indicate that in the presence of
immunocompromising disease and liver damage the infecting dose of
this potentially fatal microorganism may be extremely low20.
Studies carried out in Florida show that less than 15% of high-risk
patients were aware of the hazards associated with the consumption of
raw oysters14. Through a popular awareness program focused on the risk
of infection associated with this pathogen, the Florida Health and
Rehabilitation Service has been informing the general population and
providing gastroenterologists with clinical references and data of
relevance to patients suffering from chronic liver infection. In California
and Louisiana, raw oyster vendors are obliged to put up clearly visible
signs informing customers about the risk of consuming this product 12.
Our biological tests did not confirm the pathogenicity of the isolated
strains. The 21 mice inoculated with a V. vulnificus culture displayed no
symptoms even after 24 hours of observation. This fact may be explained
by the loss of the polysaccharide capsule without which, according to
OLIVER & KAPER20, vibrions cannot initiate an infection. SIMPSON
et al.21 observed that the absence of the capsule was tied up with the loss
of virulence of the strains; in fact, only encapsulated cells were able to
make use of transferrin-bound iron and a 103 inoculum was virulent to
mice when iron was abundant in the blood serum.
It is interesting to note that the colonies grown in TSA with 1%
NaCl for 24 hours produced no mucus and easily lost their shape at the
touch of a platinum needle. When placed under light the colonies turned
out to be translucid. According to OLIVER & KAPER20, V. vulnificus
colonies are either opaque (virulent) or translucid (not virulent). The
encapsulated form is a common type in clinical isolates and is associated
with invasion capacity, while the harmless unencapsulated form is more
common in the environment11.
It has been suggested that unencapsulated cells cannot take up
transferrin, and that only opaque cells are capable of growing in human
transferrin while resisting the bactericidal and bacteriostatic effects
inherent in human blood serum21. However, this has been questioned by
WRIGHT et al.23, who reported the growth of an unencapsulated strain
in human transferrin.
The earliest virulence tests using latent cells revealed a loss of
pathogenicity in both common and iron-primed mice17. However, recent
studies have shown that this human pathogen retains its virulence in a
non-cultivable state19. BIOSCA et al.2 found that latent cells were not
virulent to elvers or mice, regardless of the cell morphotype chosen. The
authors proposed that the loss of infectiousness of cells in a non-cultivable
state may be due to factors other than the loss of the capsule. The same
authors observed that the loss of virulence occurred only in cells stressed
by exposure to low temperatures.
When challenged with antibacterial agents, all isolated strains were
sensitive to nitrofurantoin, ciprofloxacin, gentamicin and
chloramphenicol, and resistant to ampicillin. Table 1 lists the antibiotics
which were efficient against V. vulnificus strains in the susceptibility
tests. Clindamycin, penicillin, ampicillin and sulfonamide, on the other
hand, were not efficient against the colonies. HORRÉ et al.13 likewise
evaluated the susceptibility of V. vulnificus and found it to be sensitive
to several antibiotics.
The most efficient antibiotics tested in this study were nitrofurantoine,
ciprofloxacin, gentamicin and chloramphenicol.
Studies carried out by BIOSCA et al.2 using combinations of
ampicillin with cefotaxime, tetracycline, amoxillin plus gentamicin or
chloramphenicol associated with aminoglycosides yielded satisfactory
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therapeutic results. It should be pointed out that in the case of both skin
infections and primary septicemia the use of antibiotics is highly
recommended to prevent clinical complications10. Currently the most
efficient antibiotics for the treatment of infections caused by V. vulnificus
6
 include tetracycline, the fluoroquinolones (e.g. ciprofloxacin), third
generation cephalosporines (e.g. ceftazidime) and the aminoglycosides
(e.g. gentamicin) which are therapeutically associated with ceftazidime
and tetra or doxacillin, or even doxacillin in combination with
ciprofloxacin or an aminoglycoside.
This therapeutic procedure can minimize the morbidity and mortality
associated with V. vulnificus infections. However, an indiscriminate use
of antibiotics has in some areas induced the development of resistance
in autochthonous bacteriological samples isolated from aquatic
environments. In one of their studies, BIOSCA et al.2 isolated
tetracycline- and trimethoprim-resistant biotype I strains from an aquatic
environment.
The strains were not virulent in our biological assays, but the results
of the antibiograms are a source of concern since many strains showed
resistance to antibiotics such as penicillin, ampicillin and clindamycin.
This finding is of relevance to public health professionals since it indicates
that strains with resistant genes circulate in the environment. The situation
is aggravated by the fact that exchanges or transfer of plasmids between
microorganisms in the original environment of the shrimp are likely to
have a negative impact on consumers of shrimp, especially in its raw
form.
RESUMO
Vibrio vulnificus: um fator de risco para a saúde do consumidor
de camarões
Nos últimos 30 anos várias espécies de Vibrio que vivem em
ambientes aquáticos têm sido proclamadas como vetor de doenças que
atingem o ser humano. Vibrio vulnificus é um patógeno de origem
marinha, com potencial invasor, podendo ser letal. Tem sido relacionado
com feridas infeccionadas e responsável por incontáveis casos de
gastrenterites e septicemia primária. Sua frequência em organismos
marinhos é considerada alta, principalmente em moluscos. Este trabalho
objetivou isolar e identificar cepas de Vibrio vulnificus a partir de 20
amostras de camarão sete- barbas, Xiphopenaeus kroyeri (Heller),
comercializado na feira de pescado do Mucuripe, Fortaleza, Ceará, Brasil.
O ágar TCBS foi usado para isolamento primário e as cepas confirmadas
através de provas bioquímicas eram submetidas a testes de virulência
em camundongos. Posteriormente as cepas identificadas como Vibrio
vulnificus foram testadas em relação à susceptibilidade a antimicrobianos.
De 29 cepas, isoladas de 20 amostras, sete (35%), originadas de sete
diferentes amostras, foram confirmadas como Vibrio vulnificus,
significando alta percentagem de amostras contaminadas. Nenhuma das
cepas apresentou virulência após 24 horas de observação, possivelmente
devido à perda das cápsulas pela célula. As sete cepas de Vibrio vulnificus
mostraram-se sensíveis a nitrofurantoína (NT), ciprofloxacina (CIP),
Gentamicina (GN), Cloranfenicol (CO), mas resistentes a Clindamicina
(CI), Penicilina (PN) e a Ampicilina (AP).
Table 1
Susceptibility of Vibrio vulnificus strains isolated from samples of seabob shrimp, Xiphopenaeus kroyeri (Heller), to antimicrobial agents
Strains/Samplings
Antibiotic/Disk content 1 2 6 10 14 14a 19
Nitrofurantoin (NT) / 300µg S S S S S S S
Nalidixic acid (NA) / 30µg S S S R S I R
Tetracycline (TT) / 30µg S R S S S S R
Clindamycin (CI) / 2µg R R R R R R I
Tobramycin (TB) / 10µg S S S S S S I
Ciprofloxacin (CIP) / 5µg S S S S S S S
Penicillin (PN) / 10U R R R R R R R
Gentamicin (GN) / 10µg S S S S S S S
Kanamycin (KN) / 30µg I I I S S S R
Cefotaxime (CTX) / 30µg S MS MS S S MS S
Erythromycin (EI) / 15µg S S S S S I R
Chloramphenicol (CO) / 30µg S S S S S S S
Amikacin (AM) / 30µg I I I S I S R
Ampicillin (AP) / 10µg R R R R R R R
Sulfonamide(SF) / 300µg S S R R S R R
Source: BAUER et al., 1966. R - Resistant; I - Intermediary; MS - Moderately susceptible; S- Susceptible.
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